US Broker Ratings

Brookdale Senior Living Inc. (BKD) Stock Analysis: Strong Analyst Buy Ratings and 25.49% Potential Upside

Brookdale Senior Living Inc. (NYSE: BKD), a key player in the healthcare sector, specifically within the medical care facilities industry, presents an intriguing investment opportunity for those interested in the..

Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Exploring a 14.60% Potential Upside

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) stands out in the healthcare sector, particularly within the drug manufacturing industry, for its focus on both specialty and generic pharmaceuticals. Headquartered in Rancho Cucamonga,..

Supernus Pharmaceuticals, Inc. (SUPN): Investor Outlook Highlights 21% Potential Upside

Supernus Pharmaceuticals, Inc. (SUPN), a prominent player in the healthcare sector, specifically in the specialty and generic drug manufacturing industry, has recently captured the attention of investors with its promising..

ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Exploring a 213% Potential Upside

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) has captured the attention of the healthcare investment community with its innovative approach to addressing severe allergic reactions. As a biotechnology company, ARS Pharmaceuticals is..

PTC Therapeutics, Inc. (PTCT) Stock Analysis: Exploring a 24.21% Potential Upside in the Biotech Sector

PTC Therapeutics, Inc. (NASDAQ: PTCT) is a prominent player in the biotechnology sector, specifically focusing on rare disorders. With a current market capitalization of $5.66 billion, this Warren, New Jersey-based..

Pediatrix Medical Group, Inc. (MD) Stock Analysis: Exploring a Promising 8.92% Potential Upside

Pediatrix Medical Group, Inc. (NYSE: MD) offers an intriguing proposition for investors seeking exposure to the healthcare sector, specifically within the niche market of pediatric and maternal-fetal medical care. With..

Surgery Partners, Inc. (SGRY): Growth Potential with a 64% Upside and Strong Buy Ratings

Surgery Partners, Inc. (NASDAQ: SGRY) is garnering significant attention from investors, fueled by promising analyst ratings and a compelling potential upside. Operating within the dynamic healthcare sector, this company specializes..

Apogee Therapeutics, Inc. (APGE) Stock Analysis: A Promising Biotech with Nearly 50% Upside Potential

Apogee Therapeutics, Inc. (NASDAQ: APGE) has captured the attention of investors with its robust pipeline in the biotechnology sector, focusing on innovative treatments for various inflammatory and immunological conditions. Despite..

Ocular Therapeutix, Inc. (OCUL) Investor Outlook: A Biotech with a 205% Potential Upside

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a key player in the biotechnology sector focusing on innovative ocular therapies, is capturing investor attention with a compelling potential upside of over 205%. With..

Veracyte, Inc. (VCYT) Stock Analysis: Exploring a 33% Potential Upside in Diagnostics Innovation

Veracyte, Inc. (NASDAQ: VCYT), a prominent player in the healthcare diagnostics sector, offers an intriguing investment proposition with a notable 33.33% potential upside. As a diagnostics company with a robust..

Innoviva, Inc. (INVA) Stock Analysis: Exploring a 40.97% Potential Upside for Investors

Innoviva, Inc. (NASDAQ: INVA), a biotechnology company rooted in the healthcare sector, is catching the eye of investors due to its promising potential upside. With a market capitalization of $1.75..

Beam Therapeutics Inc. (BEAM) Stock Analysis: Exploring a 72.96% Potential Upside in the Biotech Innovator

Beam Therapeutics Inc. (NASDAQ: BEAM), a pioneering biotechnology firm based in Cambridge, Massachusetts, is capturing investor attention with a staggering potential upside of 72.96%. Specializing in precision genetic medicines, Beam..

Pacira BioSciences, Inc. (PCRX) Stock Analysis: A Healthcare Innovator with 28.58% Potential Upside

Pacira BioSciences, Inc. (NASDAQ: PCRX) stands out in the healthcare sector with its innovative approach to non-opioid pain management. Headquartered in Brisbane, California, Pacira is at the forefront of developing..

Twist Bioscience Corporation (TWST) Stock Analysis: Navigating a 16.9% Revenue Growth Amidst a Challenging Market

Twist Bioscience Corporation (NASDAQ: TWST) stands at the forefront of the synthetic DNA industry, offering a unique portfolio of products that cater to various sectors, including therapeutics, diagnostics, and even..

Adaptive Biotechnologies (ADPT) Stock Analysis: Exploring a 35% Upside Potential in Biotechnology

Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a prominent player in the healthcare sector, is capturing the attention of investors with its promising growth potential and a notable upside that could reach..

IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: Unlocking a Potential 58% Upside

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a prominent player in the biotechnology sector, is making waves with its innovative approach to precision medicine oncology. With a robust pipeline and strategic partnerships,..

Belite Bio, Inc (BLTE) Stock Analysis: A Glimpse into the Biotech’s 3.43% Potential Upside

Belite Bio, Inc (BLTE), a burgeoning name in the biotechnology sector, has caught the attention of investors with its innovative approach to tackling retinal degenerative diseases. With a market capitalization..

Pulse Biosciences, Inc (PLSE) Stock Analysis: Exploring a 48.59% Potential Upside in the Healthcare Sector

Pulse Biosciences, Inc. (NASDAQ: PLSE), a burgeoning player in the healthcare sector, specifically within the Medical Instruments & Supplies industry, is capturing investor interest with a compelling potential upside of..

Tandem Diabetes Care, Inc. (TNDM) Stock Analysis: Navigating the Healthcare Sector with a 2.30% Potential Upside

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a noteworthy name in the healthcare sector, specifically within the medical devices industry. With a market capitalization of $1.92 billion, Tandem is a..

NovoCure Limited (NVCR) Investor Outlook: Exploring a Potential 129.64% Upside

For investors seeking opportunities in the healthcare sector, NovoCure Limited (NASDAQ: NVCR) presents a compelling case with its oncology-focused innovations and a significant potential upside of 129.64%. Specializing in the..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds